A fully lab-grown solid human organ is successfully transplanted into a human patient before 2032.

Question

Six frontier AI models put this at 22% by 24 Sept 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

22% — the median of 6 frontier models, resolving by 2036-09-24.

Answer

Gemini (Google): 27% — Success hinges on solving microvascular perfusion and immune scaffold degradation in thick, metabolically dense tissue. Simpler engineered tissues like bladders and skin succeeded, but thick solid organs like kidneys or livers consistently necrosce. FDA-cleared clinical trials require at least 3-5 years of large-animal survival, leaving barely six years to reach human endpoints. A working capillarized whole organ surviving >30 days in non-human primates before 2028 would push odds above 50%.

Answer

Claude (Anthropic): 22% — Depends on whether bioprinted vascularized solid organs (kidney/liver) clear animal trials and reach human transplant by 2032. Current progress is at partial organs (bladder, trachea patches) and mini-organoids, not full vascularized solid organs like kidneys or livers. Companies like Prellis and academic labs target vascularization breakthroughs in the next 5-10 years, but human trials require years of regulatory review after… A dramatic acceleration such as a successful pig-to-human style bioprinted organ trial by 2029-2030 would be the key signal to raise this estimate.

Answer

GPT (OpenAI): 63% — This hinges on whether a vascularized, adult-scale engineered organ can clear durable clinical safety and function trials by 2032. Teams must solve perfusion, innervation where needed, maturation, and GMP manufacture before regulators permit first-in-human transplantation. Engineered bladders, tracheal grafts, skin, and tissue patches set a positive precedent, but no lab-grown kidney, liver, heart, or lung has yet cleared this bar. A 2028–30 first-in-human report of a vascularized kidney or liver functioning beyond 30 days would substantially raise the odds.

Answer

Grok (xAI): 18% — Vascularized full-size kidney/liver/heart from iPSCs must clear large-animal data and first-in-human by 2031. FDA/EMA still demand multi-year primate survival data; no leading lab has an IND timeline before 2028. Xeno and bioartificial organs historically take 8–12 years from primate success to human implant; lab-grown solid organs lag that curve. A 2027 paper showing 6-month pig survival of a printed kidney would be the clearest upward revision.

Answer

DeepSeek (DeepSeek): 22% — This hinges on whether any lab-built solid organ clears human trials and keeps a patient alive past 30 days within the window. Only a handful of groups (Wake Forest, Tel Aviv, United Therapeutics, IVIVA) are near human trials, and none has a solid vascularized organ in Phase 1 yet. Bladder and trachea transplants succeeded, but those are hollow and non-vascularized; solid organs need capillary networks that bioprinting still cannot perfuse at scale. The 30-day survival bar is the killer: immune rejection and thrombosis typically emerge in weeks 1-4, and no engineered solid organ has cleared that in animals, let…

Answer

Qwen (Alibaba): 12% — Vascularization of a full-size solid organ in a human remains unsolved; no candidate is in or near a Phase I trial today. No lab-grown solid organ has cleared preclinical large-animal survival benchmarks (kidney, liver, heart) as of mid-2026; the closest work—kidney organoids from… A successful transplant requires a functioning vascular network, immune compatibility, and regulatory approval (FDA/EMA), each of which independently takes 5-10+ years… The single development that would most raise this estimate: a large-animal study showing a bioprinted or scaffold-grown kidney or liver surviving >90 days with full…

A fully lab-grown solid human organ is successfully transplanted into a human patient before 2032.

A gene therapy targeting herpes simplex virus enters Phase 3 clinical trials before 2029.

The FDA approves at least 10 novel gene therapies in a single calendar year before 2030.

A clinical trial begins treating human embryos with heritable germline gene editing before 2035.

An in vivo CRISPR gene-editing therapy receives broad regulatory approval for a common non-rare disease before 2030.